Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorderBOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, today announced the presentation of new preclinical data showing that OX2R activation with a highly potent and selective OX2R agonist reduced behavioral despair and enhanced wakefulness ...